References
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease. Updated 2014. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf ( accessed: 21 November 2014).
- Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006; 27:188–207.
- World Health Organization. Chronic Respiratory Diseases: Burden of COPD. Available from: http://www.who.int/respiratory/copd/burden/en/index.html (accessed: 21 November 2014).
- Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler. Int J Chron Obstruct Pulmon Dis 2009; 4:381–390.
- Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm 2011; 68:1221–1232.
- Bateman ED. Improving inhaler use in COPD and the role of patient preference. Eur Respir Rev 2005; 14:85–88.
- Ágh T, Inotai A, Mészáros Á. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration 2011; 82:328–334.
- Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis 2010; 5:401–406.
- Fuller R. The Diskus: a new multi-dose powder device–efficacy and comparison with Turbuhaler. J Aerosol Med1995; 8(Suppl 2):S11–S17.
- US Food, Drug Administration. Medication Guide: BREO ELLIPTA. 2013. Available from: http://www.fda.gov/downloads/drugs/drugsafety/ucm352347.pdf ( accessed 21 November 2014).
- US Food, Drug Administration. Medication Guide for ANORO ELLIPTA. 2013. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM380278.pdf ( accessed 21 November 2014).
- US Food, Drug Administration. Highlights of Prescribing Information: INCRUSE ELLIPTA. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205382s000lbl.pdf ( accessed 21 November 2014).
- European Medicines Agency. Summary of product characteristics: RELVAR ELLIPTA. 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002673/WC500157633.pdf ( accessed 21 November 2014).
- Health Canada. Summary Basis of Decision (SBD): BREO ELLIPTA. 2013. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2013_breo_ellipta_157301-eng.php ( accessed 21 November 2014).
- European Medicines Agency. Summary of product characteristics: ANORO ELLIPTA. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002751/WC500168424.pdf ( accessed 21 November 2014).
- Health Canada. Summary Basis of Decision (SBD): ANORO ELLIPTA. 2014. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_anoro_ellipta_161585-eng.php ( accessed: 21 November 2014).
- European Medicines Agency. Summary of product characteristics: INCRUSE ELLIPTA. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002809/WC500167430.pdf ( accessed: 21 November 2014).
- GlaxoSmithKline. GSK announces approval in Canada for Incruse Ellipta (umeclidinium) as a treatment for COPD. 2014. Available at: http://www.gsk.com/en-gb/media/press-releases/2014/gsk-announces-approval-in-canada-for-incruse-ellipta-umeclidin ium-as-a-treatment-for-copd/ ( accessed 21 November 2014).
- Prescott RJ. The comparison of success rates in cross-over trials in the presence of an order effect. Appl Stat 1981; 30:9–15.
- Senn, S. Cross-over Trials in Clinical Research, 2nd ed. Chichester, UK: John Wiley & Sons, Ltd., 2002: 128–131, 202–203.
- Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75:800–802.
- Agustí A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J 2014; 43:763–772.
- Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore 5, Pistolesi M, Watkins ML, Crim C, Martinez FJ. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Respir Med 2014; 108:1171–1179.
- Svedsater H, Dale P, Garrill K, et al. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med 2013; 13:72.
- Chrystyn H, Small M, Milligan G, et al. Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med 2014; 108:358–365.
- Bridges JFP, Onukwugha E, Johnson FR, Hauber ABN. ISPOR Connections 2007; 13:4–7. Available from: http://www.ispor.org/news/articles/ISPORConnections_Vol13No6_Dec15.pdf ( accessed 21 November 2014).
- Mulley AG, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients' preferences matter. Br Med J 2012; 345:e6572.
- Bourbeau J, Bartlett SJ, Patient adherence in COPD. Thorax 2008; 63:831–838.
- Fink JB, Colice GL, Hodder R. Inhaler devices for patients with COPD. COPD 2013; 10:523–535.
- Chong CA, Chen IJ, Naglie G, Krahn MD. How well do guidelines incorporate evidence on patient preferences? J Gen Intern Med 2009; 24:977–982.